GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC) announced today data from two studies presented at the 97th annual meeting of the American Association of Cancer Research (AACR) that further support the use of adenovector systems to deliver the gene for tumor necrosis factor-alpha (TNFa). GenVec’s lead product candidate, TNFerade™ biologic (TNFerade) is an adenovector, or DNA carrier, which contains the gene for TNFa, a potent immune system protein with well-documented anti-cancer effects. TNFerade is currently in a pivotal Phase II/III trial for locally advanced pancreatic cancer.
